Sorrento Therapeutics (SRNE) Competitors $0.0013 0.00 (0.00%) As of 03:21 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE vs. PRFX, ZVSA, PWUP, ONCO, PCSA, ALZN, ADTX, VCNX, PTN, and AWHShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include PainReform (PRFX), ZyVersa Therapeutics (ZVSA), PowerUp Acquisition (PWUP), Onconetix (ONCO), Heatwurx (PCSA), Alzamend Neuro (ALZN), Aditxt (ADTX), Vaccinex (VCNX), Palatin Technologies (PTN), and Aspira Women's Health (AWH). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Its Competitors PainReform ZyVersa Therapeutics PowerUp Acquisition Onconetix Heatwurx Alzamend Neuro Aditxt Vaccinex Palatin Technologies Aspira Women's Health Sorrento Therapeutics (NASDAQ:SRNE) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk. Does the media prefer SRNE or PRFX? In the previous week, PainReform had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 1 mentions for PainReform and 0 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score. Company Overall Sentiment Sorrento Therapeutics Neutral PainReform Neutral Which has more volatility and risk, SRNE or PRFX? Sorrento Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, PainReform has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Do insiders and institutionals believe in SRNE or PRFX? 0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend SRNE or PRFX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings and valuation, SRNE or PRFX? PainReform has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.01-$572.84MN/AN/APainReformN/AN/A-$14.59M-$147.33-0.01 Is SRNE or PRFX more profitable? Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A PainReform N/A N/A N/A SummaryPainReform beats Sorrento Therapeutics on 5 of the 7 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$717K$273.73M$5.70B$9.48BDividend YieldN/AN/A4.59%3.99%P/E RatioN/AN/A27.9019.95Price / Sales0.01369.83442.19102.72Price / CashN/A22.4436.5558.97Price / BookN/A11.548.635.90Net Income-$572.84M-$110.10M$3.24B$258.42M7 Day PerformanceN/A5.06%3.22%1.94%1 Month PerformanceN/A21.80%10.72%12.02%1 Year PerformanceN/A15.96%34.94%20.81% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento Therapeutics0.6185 of 5 stars$0.00flatN/A-80.6%$717K$60.32M0.00800PRFXPainReformN/A$1.40+0.7%N/A-12.7%$2.81MN/A-0.014Gap DownZVSAZyVersa Therapeutics0.0499 of 5 stars$0.57-3.8%N/A-93.8%$2.71MN/A0.002Gap DownPWUPPowerUp AcquisitionN/A$0.33-4.7%N/A-96.8%$2.56MN/A0.00N/AGap DownHigh Trading VolumeONCOOnconetix0.0837 of 5 stars$4.83+14.2%N/A-99.3%$2.56M$2.52M0.0012Positive NewsPCSAHeatwurx2.1088 of 5 stars$0.21-5.3%$2.00+833.3%-86.1%$2.55MN/A-0.0720Positive NewsGap DownALZNAlzamend Neuro2.2497 of 5 stars$3.16-1.3%$180.00+5,596.2%-91.1%$2.53MN/A0.004News CoverageUpcoming EarningsADTXAditxtN/A$1.19-0.8%N/A-100.0%$2.52M$130K0.0060Positive NewsVCNXVaccinex0.9423 of 5 stars$0.97+3.2%N/A-86.4%$2.52M$388K-0.0240Gap UpPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's HealthN/A$0.08-12.5%$5.50+6,607.3%-94.3%$2.44M$9.18M-0.07110High Trading Volume Related Companies and Tools Related Companies PainReform Competitors ZyVersa Therapeutics Competitors PowerUp Acquisition Competitors Onconetix Competitors Heatwurx Competitors Alzamend Neuro Competitors Aditxt Competitors Vaccinex Competitors Palatin Technologies Competitors Aspira Women's Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
